{
  "docId": "019de070-fa64-77bc-8caf-8d60d9bebc40",
  "docSlug": "35e598705f15db6c29b5dc7bc3a9d06d",
  "documentTitle": "Bausch Health Companies | Results Presentation Deck | 79 slides",
  "authorId": "bausch-health-companies",
  "authorName": "Bausch Health",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 56,
  "pageCount": 79,
  "prevPage": 55,
  "nextPage": 57,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "balanced",
  "nDataPoints": 25,
  "notes": "The slide provides supplemental financial metrics including R&D, G&A, Depreciation, CapEx, and Stock-Based Compensation.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-fa64-77bc-8caf-8d60d9bebc40/56",
  "deckHref": "/decks/019de070-fa64-77bc-8caf-8d60d9bebc40",
  "deckJsonHref": "/decks/019de070-fa64-77bc-8caf-8d60d9bebc40.json",
  "deckAnchorHref": "/decks/019de070-fa64-77bc-8caf-8d60d9bebc40#slide-56",
  "components": [
    {
      "bbox": {
        "h": 0.03,
        "w": 0.7,
        "x": 0.25,
        "y": 0.95
      },
      "kind": "disclaimer",
      "text": "1. The remainder of Bausch Health is referred to as \"Bausch Pharma\" and will assume a new name upon the separation of the Company's eye health business, Bausch + Lomb. 2. Estimates which are subject to change.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d72247e4-b0f0-461b-bd0a-b22f2653ae4f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.9,
        "x": 0.05,
        "y": 0.268
      },
      "kind": "table",
      "text": "Bausch Pharma 1Q21 FY20 FY19 FY18 Corporate R&D Allocation $37M $148M $146M $132M Corporate G&A Allocation $42M $162M $164M $181M Depreciation $13M $56M $54M $54M Capital Expenditures $16M $49M $84M $53M Stock-Based Compensation $15M $55M $52M $44M",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3326ae98-7fcb-480a-8b49-6786f28796f9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Bausch Pharma: Additional Financial Information",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d2d4205a-b5cc-43f4-b6ec-e9b83ff54140",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "c241bf04-b78d-4c85-b0a2-93b506bdba64",
      "evidence": "table/data: Bausch Pharma 1Q21 FY20 FY19 FY18 Corporate R&D Allocation $37M $148M $146M $132M Corporate G&A Allocation $42M $162M $164M $181M Depreciation $13M $56M $54M $54M Capital Expenditures $16M $49M $84M $53M Stoc",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 79,
      "from": 21,
      "beatId": "4729803e-b632-425a-8f97-04c24718552b",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Action",
      "beatSlug": "monroes-sequence-action",
      "evidence": "The company outlines its strategic plan and next steps",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}